Royalty Pharma (MEX:RPRXN) Inventories, Raw Materials & Components: MXN0 Mil (As of Mar. 2026)


MEX:RPRXN Royalty Pharma PLC MEX:RPRXN
72 GF Score
Price MXN775.06
GF Value MXN535.17
! 10 Warning Signs
View Full Analysis

What is Royalty Pharma Inventories, Raw Materials & Components?

Royalty Pharma MEX:RPRXN 72 Inventories, Raw Materials & Components is MXN0 Mil as of Mar. 2026. GuruFocus rates MEX:RPRXN with a GF Score™ of 72/100 and a GF Value™ of MXN535.17. The stock has 10 warning signs investors should review.

Royalty Pharma's inventories, raw materials & components for the quarter that ended in Mar. 2026 was MXN0 Mil.

Royalty Pharma Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for Royalty Pharma's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Royalty Pharma Inventories, Raw Materials & Components Chart

Royalty Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Royalty Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEX:RPRXN
72GF Score
Royalty Pharma PLC MEX:RPRXN
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Royalty Pharma Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of MXN0 Mil mean?
Royalty Pharma (MEX:RPRXN) has a Inventories, Raw Materials & Components of MXN0 Mil as of Mar. 2026. Raw materials are the components a company uses for its main products. View historical data on Royalty Pharma and its competitors.
Is Royalty Pharma's Inventories, Raw Materials & Components too high?
Royalty Pharma's current Inventories, Raw Materials & Components is MXN0 Mil. Overall, Royalty Pharma has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's Inventories, Raw Materials & Components compare to BNTX and INSM?
Royalty Pharma's Inventories, Raw Materials & Components of MXN0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Biotechnology company?
A good Inventories, Raw Materials & Components depends on the Biotechnology industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Royalty Pharma and its competitors. Royalty Pharma's current Inventories, Raw Materials & Components is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Royalty Pharma (MEX:RPRXN) has a current Inventories, Raw Materials & Components of MXN0 Mil. The stock's GF Value™ is MXN535.17, compared to a current price of MXN775.06 — trading 44.8% above its estimated fair value. The current Inventories, Raw Materials & Components is MXN0 Mil. Royalty Pharma's overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For Royalty Pharma (MEX:RPRXN), the current Inventories, Raw Materials & Components is MXN0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Royalty Pharma (MEX:RPRXN) Overvalued in 2026?

Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued. The current stock price of MXN775.06 is trading 44.8% above its estimated GF Value™ of MXN535.17.

Key valuation signals for MEX:RPRXN:

  • Inventories, Raw Materials & Components: MXN0 Mil
  • GF Value™: MXN535.17 vs. price of MXN775.06 (44.8% above fair value)
  • GF Score™: 72/100 with 10 warning signs

No single metric tells the full story. See the MEX:RPRXN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Royalty Pharma Business Description

Other Exchanges RPRX:USARPD:Germany
Address 110 East 59th Street, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
72GF Score

Get the complete analysis for MEX:RPRXN

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN775.06
Price
MXN535.17
GF Value